<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04122846</url>
  </required_header>
  <id_info>
    <org_study_id>KIMBS1</org_study_id>
    <nct_id>NCT04122846</nct_id>
  </id_info>
  <brief_title>Internet-based Emotional Awareness and Expression Therapy for Somatic Symptom Disorder</brief_title>
  <acronym>MBS1</acronym>
  <official_title>Internet-based Emotional Awareness and Expression Therapy for Somatic Symptom Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stockholm University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to conduct an initial feasibility evaluation of the new
      Internet-based EAET treatment manual. We will include 50 patients with somatic symptom
      disorder to take part of the treatment for nine weeks through the Internet. A within-subject
      design will be used. Self-report measures of symptom level and mechanisms of change will be
      conducted weekly. Feedback on content, process and potential caveats will be collected using
      surveys and written evaluations from the participants at post-treatment. Linear mixed models
      will be used to investigate trajectories of change in symptoms and processes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Actual">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Emotional Awareness and Expression Therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PHQ-15</measure>
    <time_frame>Baseline</time_frame>
    <description>Patient Health Questionnaire Physical Symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PHQ-15</measure>
    <time_frame>Weekly during treatment, for 9 weeks</time_frame>
    <description>Change in physical symptoms (as measured by the PHQ-15)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PHQ-15</measure>
    <time_frame>At study completion, after 9 weeks</time_frame>
    <description>Patient Health Questionnaire Physical Symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PHQ-15</measure>
    <time_frame>At study completion, after 4 months</time_frame>
    <description>Patient Health Questionnaire Physical Symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PHQ-9</measure>
    <time_frame>Baseline</time_frame>
    <description>Patient Health Questionnaire Depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PHQ-9</measure>
    <time_frame>At study completion, after 9 weeks</time_frame>
    <description>Patient Health Questionnaire Depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PHQ-9</measure>
    <time_frame>At study completion, after 4 months</time_frame>
    <description>Patient Health Questionnaire Depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GAD-7</measure>
    <time_frame>Baseline</time_frame>
    <description>Patient Health Questionnaire Anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GAD-7</measure>
    <time_frame>At study completion, after 9 weeks</time_frame>
    <description>Patient Health Questionnaire Anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GAD-7</measure>
    <time_frame>At study completion, after 4 months</time_frame>
    <description>Patient Health Questionnaire Anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SDS</measure>
    <time_frame>Baseline</time_frame>
    <description>Sheehan Disability Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SDS</measure>
    <time_frame>At study completion, after 9 weeks</time_frame>
    <description>Sheehan Disability Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SDS</measure>
    <time_frame>At study completion, after 4 months</time_frame>
    <description>Sheehan Disability Scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>EPS-25</measure>
    <time_frame>Baseline</time_frame>
    <description>Emotional Processing Scale (Measure of treatment process)</description>
  </other_outcome>
  <other_outcome>
    <measure>EPS-25</measure>
    <time_frame>Weekly during treatment, for 9 weeks</time_frame>
    <description>Emotional Processing Scale (Measure of treatment process)</description>
  </other_outcome>
  <other_outcome>
    <measure>EPS-25</measure>
    <time_frame>At study completion, after 9 weeks</time_frame>
    <description>Emotional Processing Scale (Measure of treatment process)</description>
  </other_outcome>
  <other_outcome>
    <measure>EPS-25</measure>
    <time_frame>At study completion, after 4 months</time_frame>
    <description>Emotional Processing Scale (Measure of treatment process)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Somatic Symptom Disorder</condition>
  <arm_group>
    <arm_group_label>Treatment (Emotional Awareness and Expression Therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Internet-based Emotional Awareness and Expression Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Emotional Awareness and Expression Therapy</intervention_name>
    <description>Very much based on &quot;Unlearn your pain&quot; by Howard Schubiner.</description>
    <arm_group_label>Treatment (Emotional Awareness and Expression Therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  A total score ≥10 on the PHQ-15

          -  A diagnosis of SSD according to the DSM-5, i.e ≥1 of the 3 of: disproportionate
             thoughts about the somatic symtom, persistently high level of anxiety, or excessive
             time and energy devoted in regard to symptoms or health concerns

          -  Symptom duration ≥6 months

          -  Written statement from a medical professional that states that a medical evaluation
             has been conducted.

        Exclusion Criteria:

          -  Alcohol or substance addiction

          -  A diagnosis of a psychological condition that might require other treatment (e.g.,
             psychosis, suicidality, etc)

          -  Other severe medical condition that might require other treatment

          -  Ongoing psychological intervention or psychotherapy that may interfere with the
             psychological treatment

          -  Ongoing medical treatment that may interfere with the psychological treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Johansson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 4, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Robert Johansson</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medically Unexplained Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

